Sema4 Holdings Corp. Stock News: Robbins LLP is Investigating Sema4 Holdings Corp. (SMFR) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Sema4 Holdings Corp. (NASDAQ: SMFR) and its officers and directors to determine whether they violated securities laws or breached fiduciary duties in failing to disclose it would reverse a material amount of previously recognized revenue and was experiencing declining sales prices for its Reproductive Health Segment. Sema4 is a health company that uses artificial intelligence to enable personalized medicine.

If you would like more information about Sema4 Holdings Corp's misconduct, click here.

What is this Case About: According to the class action complaint filed against Sema4, on August 15, 2022, the Company announced changes to its research and development leadership team, including that Eric Schadt was stepping down from his roles as President and Chief R&D Officer. The Company also disclosed that it was eliminating approximately 13% of its workforce as part of a series of restructuring and corporate realignments. During the related conference call, Sema4 revealed that it had “reversed $30.1 million of revenue this quarter related to prior periods,” in connection with negotiations with “one of [Sema4’s] larger commercial payors regarding the potential recoupment of payments for Sema4 carrier screening services rendered from 2018 to early 2022.” On this news, Sema4’s stock fell $0.80, or 33.3%, to close at $1.60 per share on August 16, 2022.

Next Steps: If you acquired shares of Sema4 Holdings Corp (SMFR) between March 14, 2022 and August 15, 2022, you have legal options. Contact Robbins LLP for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Sema4 Holdings Corp settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:SMFR

Release Summary

Sema4 Holdings Corp. failed to disclose it was experiencing declining sales prices for its Reproductive Health Segment.

Release Versions

$Cashtags

Hashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles

Robbins LLP

More News From Robbins LLP

Robbins LLP Urges KD Stockholders to Contact the Firm for Information About the Class Action Against Kyndryl Holdings, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Kyndryl Holdings, Inc. (NYSE: KD) securities between August 7, 2024 and February 9, 2026. Kyndryl describes itself as a “technology services company, which engages in the provision of infrastructure services.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? Au...

Robbins LLP Reminds Inovio Pharmaceuticals, Inc. Stockholders of the Pending Class Action Against INO and Urges Harmed Stockholders to Seek More Information

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...

Robbins LLP Reminds ENPH Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Enphase Energy, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Enphase Energy, Inc. (NASDAQ: ENPH) securities between April 22, 2025 and October 28, 2025. Enphase is a global energy technology company focusing on solutions for solar generation, storage, and communication. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? Ap...

Back to Newsroom